A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors
Latest Information Update: 13 Apr 2025
At a glance
- Drugs XTX 301 (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Xilio Therapeutics
- 11 Mar 2025 According to Oncolytics Biotech media release, A maximum tolerated dose has not yet been established, and Xilio continues to enroll patients in Phase 1A monotherapy dose escalation and Phase 1B monotherapy dose expansion of the ongoing Phase 1 clinical trial of XTX301.
- 22 Jan 2025 According to Oncolytics Biotech media release, Xilio Therapeutics forward to sharing initial Phase 2 data for the combination in MSS CRC at ASCO GI in January.
- 19 Dec 2024 According to a Xilio Therapeutics media release, as of the data cutoff date of November 25, 2024, 34 patients with advanced solid tumors had been treated with XTX301.